Active — Not RecruitingNot Applicable

A Study Using Human Papillomavirus (HPV) DNA Testing to Detect HPV-Related Oropharyngeal Cancer (OPC)

United States9 participantsStarted 2023-03-31

Plain-language summary

The researchers think that a blood test (NavDx®) may be able to identify cancer early by looking for circulating DNA from Human Papillomavirus/HPV. Circulating DNA are small pieces of genes that are released into the bloodstream. The purpose of this study is to find out whether using this blood test to test for HPV DNA will help detect HPV-related Oropharyngeal Cancer/OPC.

Who can participate

Age range45 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Ages 45 and older * Self-reported history of four or more lifetime sexual partners * Self-reported history of one or more lifetime oral sexual partner * No previous history of diagnosed HPV-related head and neck cancer Exclusion Criteria: * History of diagnosed HPV-related OPC * Less than three sexual partners in lifetime * No history of oral sex performed * Younger than age 45

What they're measuring

Proportion of participants found to have HPV-related OPC

Timeframe: Up to 5 years

Trial details

NCT IDNCT05814549

SponsorMemorial Sloan Kettering Cancer Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2031-03-31

View on ClinicalTrials.gov More Oropharyngeal Cancer trials